You are here: Industry Insights > Nordisk

News List

Lilly’s tirzepatide beats Ozempic in head-to-head type 2 diabetes trial pharmatimes
June 29, 2021
Eli Lilly has announced that its investigational GIP and GLP-1 inhibitor tirzepatide showed superiority over Novo Nordisk’s Ozempic in a Phase III trial.
FDA approves oral semaglutide Rybelsus to treat type 2 diabetes pharmaceutical-technology
September 26, 2019
FDA approval comes from results from ten PIONEER clinical trials conducted in a total of 9,543 adult type 2 diabetes patients.
Novo Nordisk to provide discounted insulin products in US pharmaceutical-technology
September 10, 2019
Dutch pharmaceutical company Novo Nordisk has announced plans to sell authorised generics of its insulin drug Novolog at a reduced price in the US.
Novo Nordisk files lawsuit against Mylan for generic application europeanpharmaceuticalreview
August 27, 2019
The two pharmaceutical companies are facing a legal battle after Mylan filed a new drug application for a generic of Novo Nordisk’s Victoza.
Novo Nordisk licenses kidney disease drug from Epigen fiercebiotech
May 29, 2018
Novo Nordisk has picked up the worldwide rights to a kidney disease drug in development at Epigen.
Novo Nordisk increases commitment to stem cell-based therapies worldpharmanews
May 23, 2018
Novo Nordisk today announced an increased commitment to stem cell-based therapies and an expansion of the focus on type 1 diabetes into other serious chronic diseases. This has been made possible